Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | ACACB | O00763 | 4/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.43 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 2/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.41 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.41 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.40 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14809489 | 0.84 | TP53 (0.41) | RXFP1ACACBSMN1; SMN2NPC1RAB9A | |
| SCHEMBL9910804 | 0.78 | RXFP1 (0.54) | RXFP1CASP3SENP7SENP8SENP6 | |
| SCHEMBL9910805 | 0.76 | RXFP1 (0.51) | RXFP1CASP3SENP7SENP8SENP6 | |
| SCHEMBL913930 | 0.74 | RXFP1 (0.53) | RXFP1CASP3SENP7SENP8SENP6 | |
| SCHEMBL30739004 | 0.74 | RXFP1 (0.53) | RXFP1CASP3SENP7SENP8SENP6 | |
| SCHEMBL17752214 | 0.72 | RXFP1 (0.50) | RXFP1CASP3SENP7SENP8SENP6 | |
| SCHEMBL14809386 | 0.72 | NPC1 (0.40) | SMN1; SMN2NPC1RAB9AMAPK1RECQL | |
| SCHEMBL6714830 | 0.72 | RXFP1 (0.75) | RXFP1DGAT1SMN1; SMN2CYP1A2NPC1 | |
| SCHEMBL608849 | 0.71 | ACACB (0.44) | ACACBSMN1; SMN2RAB9AALDH1A1LMNA | |
| SCHEMBL14808848 | 0.71 | ACACB (0.44) | ACACBSMN1; SMN2NPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2448584-B1 | SUBSTITUTED 4-HYDROXYPYRIMIDINE-5-CARBOXAMIDES | MERCK SHARP & DOHME (US) | 2014-12-31 | — | — | EP | disclosed |
| EP-2448584-B1 | SUBSTITUTED 4-HYDROXYPYRIMIDINE-5-CARBOXAMIDES | MERCK SHARP & DOHME (US) | 2014-12-31 | — | — | EP | disclosed |
| US-8372857-B2 | Substituted 4-hydroxypyrimidine-5-carboxamides | MERCK SHARP & DOHME CORP. (US) | 2013-02-12 | — | — | US | disclosed |
| US-8372857-B2 | Substituted 4-hydroxypyrimidine-5-carboxamides | MERCK SHARP & DOHME CORP. (US) | 2013-02-12 | — | — | US | disclosed |
| CN-102802628-A | Substituted 4-hydroxypyrimidine-5-carboxamides | MERCK SHARP & DOHME | 2012-11-28 | — | — | CN | disclosed |
| US-20120142694-A1 | SUBSTITUTED 4-HYDROXYPYRIMIDINE-5-CARBOXAMIDES | MERCK SHARP & DOHME CORP. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120142694-A1 | SUBSTITUTED 4-HYDROXYPYRIMIDINE-5-CARBOXAMIDES | MERCK SHARP & DOHME CORP. (US) | 2012-06-07 | — | — | US | disclosed |
| EP-2448584-A1 | SUBSTITUTED 4-HYDROXYPYRIMIDINE-5-CARBOXAMIDES | Merck Sharp & Dohme Corp. (US) | 2012-05-09 | — | — | EP | disclosed |
| WO-2011002624-A1 | SUBSTITUTED 4-HYDROXYPYRIMIDINE-5-CARBOXAMIDES | MERCK SHARP & DOHME CORP. (US) | 2011-01-06 | — | — | WO | disclosed |
| WO-2011002624-A1 | SUBSTITUTED 4-HYDROXYPYRIMIDINE-5-CARBOXAMIDES | MERCK SHARP & DOHME CORP. (US) | 2011-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142694-A1 | SUBSTITUTED 4-HYDROXYPYRIMIDINE-5-CARBOXAMIDES | HIF1AN, EGLN2, EGLN3 | RXFP1 1606/4885ACACB 2603/4885ADORA3 3499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.